These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1206400)

  • 21. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
    Westin JE; Lindgren HS; Gardi J; Nyengaard JR; Brundin P; Mohapel P; Cenci MA
    J Neurosci; 2006 Sep; 26(37):9448-61. PubMed ID: 16971529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CNS drug delivery: opioid peptides and the blood-brain barrier.
    Witt KA; Davis TP
    AAPS J; 2006 Feb; 8(1):E76-88. PubMed ID: 16584136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of neuropeptide drugs that cross the blood-brain barrier.
    Egleton RD; Davis TP
    NeuroRx; 2005 Jan; 2(1):44-53. PubMed ID: 15717056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.
    Murata M; Mizusawa H; Yamanouchi H; Kanazawa I
    J Neural Transm (Vienna); 1996; 103(10):1177-85. PubMed ID: 9013404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man.
    Lennernäs H; Nilsson D; Aquilonius SM; Ahrenstedt O; Knutson L; Paalzow LK
    Br J Clin Pharmacol; 1993 Mar; 35(3):243-50. PubMed ID: 8471400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration.
    Bredberg E; Lennernäs H; Paalzow L
    Pharm Res; 1994 Apr; 11(4):549-55. PubMed ID: 8058614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Where do the depleted plasma amino acids go in phenylketonuria?
    Christensen HN
    Biochem J; 1986 Jun; 236(3):929-30. PubMed ID: 3790098
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.
    Greig NH; Sweeney DJ; Rapoport SI
    Cancer Chemother Pharmacol; 1988; 21(1):1-8. PubMed ID: 3342460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of anti-parkinsonian drugs.
    Cedarbaum JM
    Clin Pharmacokinet; 1987 Sep; 13(3):141-78. PubMed ID: 3311529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance.
    Frankel JP; Kempster PA; Bovingdon M; Webster R; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1989 Sep; 52(9):1063-7. PubMed ID: 2795076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa.
    Nutt JG; Woodward WR; Carter JH; Trotman TL
    J Neurol Neurosurg Psychiatry; 1989 Apr; 52(4):481-7. PubMed ID: 2738591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of amino acid transport systems in cultured human umbilical vein endothelial cells.
    Mann GE; Pearson JD; Sheriff CJ; Toothill VJ
    J Physiol; 1989 Mar; 410():325-39. PubMed ID: 2677320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for inhibition of exodus of small neutral amino acids from non-brain tissues in hyperphenylalaninaemic rats.
    de Cespedes C; Thoene JG; Lowler K; Christensen HN
    J Inherit Metab Dis; 1989; 12(2):166-80. PubMed ID: 2502675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.
    Bowes SG; O'Neill CJ; Nicholson PW; Leeman AL; Deshmukh AA; Dobbs RJ; Dobbs SM
    Eur J Clin Pharmacol; 1991; 41(5):459-62. PubMed ID: 1761074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.
    Deleu D; Ebinger G; Michotte Y
    Eur J Clin Pharmacol; 1991; 41(5):453-8. PubMed ID: 1761073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current drug therapy for Parkinson's disease. A review.
    Coleman RJ
    Drugs Aging; 1992; 2(2):112-24. PubMed ID: 1596594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of DOPA-induced arousal in reserpine-treated rabbits and mice by histidine.
    Abou YZ; Farjo IB
    Br J Pharmacol; 1979 Feb; 65(2):303-9. PubMed ID: 760904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolated microvessels: the blood-brain barrier in vitro.
    Hjelle JT; Baird-Lambert J; Cardinale G; Specor S; Udenfriend S
    Proc Natl Acad Sci U S A; 1978 Sep; 75(9):4544-8. PubMed ID: 279933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier.
    Wade LA; Katzman R
    J Neurochem; 1975 Dec; 25(6):837-42. PubMed ID: 1206400
    [No Abstract]   [Full Text] [Related]  

  • 40. 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.
    Wade LA; Katzman R
    Life Sci; 1975 Jul; 17(1):131-6. PubMed ID: 1143006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.